By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up ...

Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter earnings above Wall Street estimates, as sustained demand for ...

Thus far, Pfizer's obesity efforts have crashed and burned. Last year, the pharmaceutical giant threw in the towel on ...

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...

Weight-loss and fertility medicines sold by Novo Nordisk, Eli Lilly, EMD and others will be included on the discount medicine ...